No Data
Hualan Biological Vaccine's (SZSE:301207) Shareholders Have More To Worry About Than Only Soft Earnings
Hualan Vaccine: Report for the third quarter of 2024
Hualan Vaccine (301207.SZ): Net income in the first three quarters was 0.267 billion yuan, a year-on-year decrease of 57.54%.
Galenghui October 29th | Hualan Vaccine (301207.SZ) announced the third quarter report of 2024, with the company's revenue reaching 0.957 billion yuan in the first three quarters, a year-on-year decrease of 44.28%; the net income attributable to the company's shareholders was 0.267 billion yuan, a year-on-year decrease of 57.54%; the net income attributable to the company's shareholders excluding non-recurring gains and losses was 0.196 billion yuan, a year-on-year decrease of 64.65%; the basic earnings per share was 0.4463 yuan.
We Think Hualan Biological Vaccine (SZSE:301207) Can Manage Its Debt With Ease
Hualan Vaccine (301207.SZ): Currently, there is no cooperation with foreign giants companies.
On September 20th, Gelonghui announced that Hualan Vaccine (301207.SZ) has consistently adhered to independent research and development, as well as the combination of industry, academia, and research, and has collaborated with domestic high-level universities, research institutes, and other institutions to carry out a series of cooperative research and development work. Currently, there is no collaboration with foreign giants.
HL VACCINE (301207.SZ): Among the vaccines currently in the registration process, there is still no vaccine with antibodies against monkeypox.
On September 20th, GeLongHui reported that Hualan Vaccine (301207.SZ) stated on the investor interactive platform that the company has entered the registration process for a vaccine product under research, and there is currently no vaccine with antibodies against smallpox. The company will continue to focus on cutting-edge vaccine categories and steadily advance the research and development of products under research.